explore -WSS

explore

author：comprehensive 2025-10-02 18:47:50 - browse：9

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： What we need to know about Arena Bioworks

WSS

Medical experts are missing from AI regulatory conversations

Why the Crimean Bridge is key to Russia's war in Ukraine

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Time to name cancers by genetics, not organ of origin, expert says

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Ebola public health emergency is over, WHO declares

focus

explore

explore

Medicare proposal to cover medical devices draws a mixed reaction

Congressmen charge Covid hearing ‘could have been an email’

How to save PrEP access — and even expand it

Vertex non

Affirmative action in medical school literally saved lives

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Virginia high school admissions case could be legal follow

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Even great ERs can’t make up for American health disparities

focus

What we need to know about Arena Bioworks

Some dementia cases could be undiagnosed liver disease

New Ultima Genomics DNA sequencer can read genome for $100

Biden administration opens offers in Medicare drug price negotiations

Why the Crimean Bridge is key to Russia's war in Ukraine

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

hotspot

Wikipedia

focus

focus